BSE filing, NSE: MEL. Summary written from the filing by ALFA Finder's alert engine.
JMJ Fintech Ltd: key numbers
- Share price
- ₹9.29
- Market cap
- ₹34.62 Cr
- Revenue (annual)
- ₹21.82 Cr
- Net profit (annual)
- ₹7.60 Cr
- P/E (TTM)
- 4.1×Sector 19.7×
- Promoter holding
- 24.18%+0.91% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from JMJ Fintech Ltd
All →JMJ Fintech Annual General Meeting
JMJ Fintech Limited seeks shareholder approval via postal ballot for three director appointments and re-designations. Remote e-voting runs from 27 October to 25 November 2026.
JMJ Fintech Board Meeting Date
JMJ Fintech Ltd has given notice of a board meeting on 03 November 2026 to approve unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the outcome.
JMJ Fintech Management Change
JMJ Fintech Limited announced the re-designation and re-appointment of its executive directors, including Johny Madathumpady Lonappan and Joju Madathumpady Johny, effective December 2026.
JMJ Fintech Debt & Borrowing: ₹7 Cr
JMJ Fintech Limited approved the issuance of NCDs aggregating up to Rs.7 Crore on a private placement basis. The Board also announced various director reappointments.
- Value
- ₹7.00 Cr
JMJ Fintech Debt & Borrowing: ₹1.9 Cr
JMJ Fintech issued a corrigendum revising the NCD allotment to 1,900 units, aggregating to ₹1.90 Crore, correcting a clerical error from the previous board meeting outcome.
- Value
- ₹1.90 Cr
JMJ Fintech Debt & Borrowing: ₹7 Cr
JMJ Fintech Limited approved the allotment of 2,000 secured NCDs totaling Rs. 2 Crore. The board also authorized a Rs. 5 Crore loan facility from Shriram Finance.
- Value
- ₹7.00 Cr
- From
- Shriram Finance Limited
- Execution
- 3-5 years
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.